Cleared Traditional

ADVIA Centaur EBV-VCA IgM

K233606 · Biokit, S.A. · Microbiology
Aug 2024
Decision
272d
Days
Class 1
Risk

About This 510(k) Submission

K233606 is an FDA 510(k) clearance for the ADVIA Centaur EBV-VCA IgM, a Epstein-barr Virus, Other (Class I — General Controls, product code LSE), submitted by Biokit, S.A. (Lli?? D?Amunt, Barcelona, ES). The FDA issued a Cleared decision on August 7, 2024, 272 days after receiving the submission on November 9, 2023. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3235.

Submission Details

510(k) Number K233606 FDA.gov
FDA Decision Cleared SESE
Date Received November 09, 2023
Decision Date August 07, 2024
Days to Decision 272 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LSE — Epstein-barr Virus, Other
Device Class Class I — General Controls
CFR Regulation 21 CFR 866.3235

Similar Devices — LSE Epstein-barr Virus, Other

All 55
LIAISON? VCA IgG and LIAISON? VCA IgG Serum Control Set; LIAISON? EBNA IgG and LIAISON? EBNA IgG Serum Control Set
K162961 · DiaSorin, Inc. · Jan 2017
LIAISON? EA IgG and LIAISON? EA IgG Serum Control Set
K162959 · DiaSorin, Inc. · Jan 2017
SERAQUEST EBV EA-D IGG TEST
K091260 · Quest Intl., Inc. · Jun 2009
PLEXUS EBV IGG MULTI-ANALYTE DIAGNOSTICS, MODEL: MP0500G
K073382 · Focus Diagnostics, Inc. · Jul 2008
BIOPLEX 2200 EBV IGG PANEL FOR BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062211 · Bio-Rad Laboratories, Inc. · Dec 2006
BIOPLEX 2200 EBV IGM PANEL ON BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062213 · Bio-Rad Laboratories, Inc. · Dec 2006